Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Propafenone 300 mg Tablets in Healthy Subjects
NCT03915340Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of propafenone in Cardiac arrhythmias (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve from Time 0 to Last Observed Quantifiable Concentration. Started Mar 2019; status: completed.
02
Drugs
propafenone
03
Conditions
Cardiac arrhythmias
Beyond the preview
Go deeper on NCT03915340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915340.